Nasdaq · CIK 0001125345
MGNX MACROGENICS INC
Insider trading from SEC Form 4. Last filing 6 d ago. Close $3.74 on Oct 9, 2026, +181% from the 52-week low and -23% from the high.
In brief
MACROGENICS INC (MGNX) has 51 SEC Form 4 filings on file from 16 insiders, the latest filed on Oct 7, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $129k, net -$129k.
3 open-market trades have been scored at MGNX. The newest: Jeffrey Stuart Peters (Senior VP, GC, and Secretary) sold $129k of stock on Aug 19, 2026, filed Aug 20, 2026, scored 26 (weak), under a 10b5-1 plan. The largest of the 3 shown: Ezio Bonvini (Sr VP, Research & CSO) sold $190k on Dec 20, 2023, scored 12 (weak), under a 10b5-1 plan.
15 Form 144 notices of planned sales are on file, the latest filed Sep 21, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MACROGENICS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Jeffrey Stuart Peters Senior VP, GC, and Secretary sell | $129k 31,105 shares | -100% | +214% from low-14% from high | |
| 36Weak | William K Heiden director buy | $151k 100,000 shares | +909% | - | |
| 12Weak | Ezio Bonvini Sr VP, Research & CSO sell | $190k 18,880 shares | -16% | +119% from low0% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 21, 2026 | Thomas Spitznagel Former Officer | 15,811 0.02% of outstanding | $66k | Sep 21, 2026 | $76k |
| Aug 19, 2026 | Jeffrey Peters Officer | 31,105 0.05% of outstanding | $129k | Aug 19, 2026 | none |
| Aug 17, 2026 | Jay Siegel Former Director | 42,080 0.07% of outstanding | $176k | Aug 17, 2026 | $131k |
| Aug 3, 2026 | Jay Siegel Former Director | 34,916 0.05% of outstanding | $131k | Aug 3, 2026 | none |
| Jul 13, 2026 | Thomas Spitznagel Former Officer | 17,000 0.03% of outstanding | $76k | Jul 13, 2026 | none |
| Mar 6, 2024 | Peters Jeffrey Stuart Officer | 19,625 0.03% of outstanding | $412k | Mar 6, 2024 | $1.5M |
| Mar 4, 2024 | Karrels James Officer | 30,000 0.05% of outstanding | $615k | Mar 4, 2024 | none |
| Mar 4, 2024 | Risser Eric Blasius Officer | 41,159 0.07% of outstanding | $816k | Mar 4, 2024 | none |
| Mar 4, 2024 | Spitznagel Thomas Officer | 10,000 0.02% of outstanding | $200k | Mar 4, 2024 | none |
| Feb 26, 2024 | Peters Jeffrey Stuart Officer | 16,124 0.03% of outstanding | $276k | Feb 26, 2024 | $1.3M |
| Feb 7, 2024 | Bonvini Ezio Officer | 3,334 0.01% of outstanding | $60k | Feb 7, 2024 | $550k |
| Feb 5, 2024 | Peters Jeffrey Stuart Officer | 76,251 0.12% of outstanding | $1.3M | Feb 5, 2024 | none |
| Feb 1, 2024 | Bonvini Ezio Officer | 13,316 0.02% of outstanding | $200k | Feb 1, 2024 | $350k |
| Jan 19, 2024 | Bonvini Ezio Officer | 13,316 0.02% of outstanding | $160k | Jan 19, 2024 | $190k |
| Dec 20, 2023 | Bonvini Ezio Officer | 18,880 0.03% of outstanding | $190k | Dec 20, 2023 | none |
Transactions
The newest 50 of 187 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Ezio Bonvini Sr VP, Research & CSO | MOption exercise Common Stock | +8,000 | $2.60 | $21k | 193,799 | 6 d ago |
| Oct 6, 2026 | Ezio Bonvini Sr VP, Research & CSO | MOption exercise Employee Stock Option (right to buy)derivative | -8,000 | $2.60 | $21k | 80,000 | 6 d ago |
| Aug 19, 2026 | Jeffrey Stuart Peters Senior VP, GC, and Secretary | SOpen-market sale Common Stock10b5-1 | -31,105 | $4.15 | $129k | 0 | Aug 20, 2026 |
| Aug 17, 2026 | Ezio Bonvini Sr VP, Research & CSO | MOption exercise Common Stock | +40,000 | $2.60 | $104k | 185,799 | Aug 18, 2026 |
| Aug 17, 2026 | Ezio Bonvini Sr VP, Research & CSO | MOption exercise Employee Stock Option (right to buy)derivative | -40,000 | $2.60 | $104k | 88,000 | Aug 18, 2026 |
| May 18, 2026 | Scott Thomas Jackson director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | William K Heiden director | MOption exercise Common Stock | +3,750 | - | - | 114,750 | May 20, 2026 |
| May 18, 2026 | Federica F. O'Brien director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | Margaret Liu director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | David C Stump director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | Meenu Chhabra director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | Karen Jean Ferrante director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 18, 2026 | Jay Philip Siegel director | MOption exercise Common Stock | +3,750 | - | - | 14,750 | May 20, 2026 |
| May 19, 2026 | Scott Koenig President and CEO | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 18, 2026 | Edward Hurwitz director | MOption exercise Common Stock | +3,750 | - | - | 47,824 | May 20, 2026 |
| May 18, 2026 | Scott Thomas Jackson director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | Margaret Liu director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | Federica F. O'Brien director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | David C Stump director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 19, 2026 | Scott Koenig President and CEO | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | Meenu Chhabra director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 18, 2026 | Jay Philip Siegel director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | Karen Jean Ferrante director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | William K Heiden director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 18, 2026 | Edward Hurwitz director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 19, 2026 | Karen Jean Ferrante director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Margaret Liu director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Federica F. O'Brien director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | William K Heiden director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | David C Stump director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Edward Hurwitz director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Scott Thomas Jackson director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Meenu Chhabra director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | Karen Jean Ferrante director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | Margaret Liu director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | Federica F. O'Brien director | AGrant or award Restricted Stock Unitderivative | +3,750 | $0.00 | $0 | 3,750 | May 20, 2026 |
| May 19, 2026 | William K Heiden director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | David C Stump director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 19, 2026 | Edward Hurwitz director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| May 18, 2026 | Meenu Chhabra director | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 0 | May 20, 2026 |
| May 19, 2026 | Scott Thomas Jackson director | AGrant or award Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 20, 2026 |
| Feb 15, 2026 | Beth Ann Smith VP, Controller & Treasurer | MOption exercise Common Stock | +1,095 | - | - | 13,204 | Feb 17, 2026 |
| Feb 15, 2026 | Ezio Bonvini Sr VP, Research & CSO | MOption exercise Common Stock | +16,665 | - | - | 152,232 | Feb 17, 2026 |
| Feb 15, 2026 | James Karrels SVP and CFO | MOption exercise Common Stock | +14,999 | - | - | 211,827 | Feb 17, 2026 |
| Feb 15, 2026 | Jeffrey Stuart Peters Senior VP, GC, and Secretary | MOption exercise Common Stock | +13,332 | - | - | 36,252 | Feb 17, 2026 |
| Feb 15, 2026 | Thomas Spitznagel Sr VP, Technical Ops | MOption exercise Common Stock | +13,332 | - | - | 44,063 | Feb 17, 2026 |
| Feb 15, 2026 | Scott Koenig President and CEO | MOption exercise Common Stock | +21,165 | $0.00 | $0 | 867,240 | Feb 17, 2026 |
| Feb 15, 2026 | Eric Blasius Risser President and CEO | MOption exercise Common Stock | +16,665 | - | - | 83,602 | Feb 17, 2026 |
| Feb 15, 2026 | Ezio Bonvini Sr VP, Research & CSO | FTax withholding Common Stock | -6,433 | $1.71 | $11k | 145,799 | Feb 17, 2026 |
| Feb 15, 2026 | James Karrels SVP and CFO | FTax withholding Common Stock | -5,790 | $1.71 | $9,901 | 206,037 | Feb 17, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Ezio BonviniSr VP, Research & CSO
- Meenu Chhabradirector
- Karen Jean Ferrantedirector
- William K Heidendirector
- Edward Hurwitzdirector
- Scott Thomas Jacksondirector
- James KarrelsSVP and CFO
- Scott KoenigPresident and CEO
- Margaret Liudirector
- Federica F. O'Briendirector
- Jeffrey Stuart PetersSenior VP, GC, and Secretary
- Eric Blasius RisserPresident and CEO
- Jay Philip Siegeldirector
- David C Stumpdirector
- Beth Ann SmithVP, Controller & Treasurer
- Thomas SpitznagelSr VP, Technical Ops
Questions about MGNX
Answered from the filings on this page, as of the latest one.
Are insiders buying MGNX?
As of Oct 7, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $129k by 1 insider at MACROGENICS INC in the last 90 days, net -$129k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade MGNX on the open market?
Jeffrey Stuart Peters (Senior VP, GC, and Secretary) sold $129k of MGNX on Aug 19, 2026 and filed the Form 4 on Aug 20, 2026. InsiderTell scored 26 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at MACROGENICS INC?
16 people have filed a Form 4 at MACROGENICS INC, among them Ezio Bonvini (Sr VP, Research & CSO), Meenu Chhabra (director), Karen Jean Ferrante (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.